trial fibrillation (AF) is the most common cardiac arrhythmia, and radiofrequency (RF) catheter ablation has become an established invasive strategy for drugrefractory AF. 1 This procedure, however, requires great attention to prevent both thromboembolic and hemorrhagic complications such as cerebral infarctions and cardiac tamponade. [1] [2] [3] Several studies have shown that the periprocedural continuation of therapeutic warfarin could reduce thromboembolic complications without increasing the risk of hemorrhagic complications. [4] [5] [6] [7] [8] [9] In addition, it has been reported that cardiac tamponade as a complication of AF ablation is not difficult to manage when the procedure is performed under therapeutic international normalized ratio (INR). 9 
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Recently, dabigatran has been used as an alternative to warfarin, offering efficacy, safety and convenience for many patients with AF. 10-14 Therefore, the use of dabigatran might be useful and safe for periprocedural anticoagulation in patients undergoing RF catheter ablation of AF. Few studies, however, have evaluated this, and in the literature the periprocedural use of dabigatran has not been examined at a lower dose of 110 mg twice daily. Accordingly, the present study was undertaken to clarify this point.
Methods

Subjects
The study included 211 patients with drug-refractory, paroxysmal or persistent AF (49 women; mean age, 62±10 years) who underwent RF catheter ablation between April 2011 and January 2012. Among them, 110 patients received dabigatran etexilate (Pradaxa ® ) at a dose of 110 mg twice daily (group D) and the remaining 101 received dose-adjusted warfarin (group W; Table 1 ). The efficacy and safety of the periprocedural use were analyzed retrospectively. The exclusion criteria were: age >75 years; advanced structural heart disease including moderate-to-severe valvular stenosis or insufficiency; congenital heart disease; left ventricular ejection fraction <45%; left atrial diameter >55 mm; myocardial infarction or coronary artery bypass graft surgery within the last 3 months; creatinine clearance <50 ml/min; chronic obstructive pulmonary disease treated with β-sympathomimetic drugs; severe respiratory insufficiency; known bleeding diathesis or intolerance to heparin or oral anticoagulants; previous attempted AF ablation; left atrial thrombus; and severe comorbidities. Ethics approval was obtained from the institutional review committee, and all patients gave informed written consent before participation.
Periprocedural Anticoagulant Treatment Protocol
In group D, all patients received 110 mg of dabigatran twice daily. Dabigatran was discontinued on the morning of the ablation procedure, and it was restarted from the next morning after the procedure with the same dose as before the procedure (Figure) . In group W, all patients received warfarin with a target INR of 2.0-3.0. Dose-adjusted warfarin (INR >2.0) had been maintained for at least 1 month before the procedure in all patients. Warfarin was continued at a maintenance dose (INR 2.0-3.0) during and after the procedure.
In all patients in the 2 groups, transesophageal echocardiography was performed within 24 h prior to the procedure. I.v. heparin was given to maintain an activated clotting time of 300 to 350 s during the procedure in both groups. After the procedure, 10,000 U heparin were given for 24 h in both groups.
RF Catheter Ablation
Extensive encircling pulmonary vein isolation (EEPVI) was performed using the double-Lasso technique under conscious sedation with propofol. 15 After a transseptal catheterization, two 7-Fr decapolar ring catheters (Lasso, Biosense Webster, Diamond Bar, CA, USA) and a 7.5-Fr irrigation catheter with a 3.5-mm distal electrode (Thermocool, Biosense Webster) were inserted into the left atrium (LA). The right-sided and leftsided circular lesions encircling the ipsilateral pulmonary veins 
Examination Protocols and Measurement Variables
A detailed general physical examination including a neurological assessment was performed before the ablation, 2 h after the ablation, and before discharge. In selected patients, cerebral magnetic resonance imaging (MRI) was also performed on the next day after the procedure. An acute cerebral embolism was defined as a focal hyperintense lesion detected on fluid attenuated inversion recovery sequence, corresponding to a restricted diffusion signal in the diffusion-weighted sequence, confirmed on apparent diffusion coefficient mapping to rule out a shine-through artifact. Transthoracic echocardiography was performed in all patients on the next day and 2-4 weeks after the procedure. After leaving the hospital, the patients underwent follow-up at 2-4 weeks, and then every month at the cardiology clinic. At each clinic visit, the patients underwent intensive questioning regarding any thromboembolism-related symptoms and a systematic neurological examination. Death, thromboemboli (stroke, transient ischemic attack, or systemic embolus), serious bleeding (intracranial hemorrhage, fall in the hemoglobin level >2 g/dl, or need for blood transfusion), minor bleeding and withdrawal from the study (intolerance/side-effects of the treatment and INR >4.5 on 2 occasions) from the enrollment to at least 2 months after the ablation were the outcome measures. 20 
Statistical Analysis
Continuous variables are expressed as mean ± SD, and were compared using Student's t-test. Categorical variables were compared using a chi-square test or Fisher exact test. An overall chi-square test for a 2×n table was performed when comparisons involved >2 groups. P<0.05 was considered significant.
Results
Baseline and Procedural Characteristics
In group D, the mean duration of preprocedural dabigatran use was 26±43 days (range, 1-280 days). Dabigatran was given to patients who rejected long-term use, for at least 1 day before the procedure, and for at least 1 month after the procedure. Further, in group W, warfarin was given at least 1 month before the procedure, and the INR on the day before the procedure was 2.4±0.4. The baseline demographic and clinical characteristics are listed in Table 1 . There was no significant difference between the 2 groups in terms of the gender, prevalence of hypertension, presence of diabetes mellitus, previous history of heart failure or strokes/transient ischemic attacks, the CHADS2 score, or the HAS-BLED score. In group D, however, the mean age was younger (P<0.05), and the prevalence of persistent AF was lower (P<0.0001) and the left atrial diameter was smaller (P<0.01) than in group W, although Figure. Protocol for periprocedural anticoagulation. Dabigatran was given on the evening before the atrial fibrillation (AF) ablation ( ), and discontinued on the morning and evening of the procedure ( ), and restarted from the next morning after the procedure ( ). Warfarin was continued through the procedure at a maintenance dose (international normalized ratio 2.0-3.0). In both groups, heparin was given to maintain an activated clotting time (ACT) of 300-350 s during the procedure, and 10,000 U heparin was injected for 24 h after the procedure. KASENO K et al.
the left ventricular ejection fraction was comparable between the 2 groups.
No patients in the 2 groups discontinued treatment (dabigatran or warfarin) before the procedure because of adverse events. None of the patients in either group had an atrial thrombus detected on transesophageal echocardiography within 24 h prior to the procedure. Before the ablation, none of the patients in the 2 groups had any neurologically abnormal findings. All patients underwent successful electrical isolation of all identified pulmonary veins. The ablation procedural parameters, except for the prevalence of additional substrate modification, did not differ between the 2 groups ( Table 1) . No evidence of any clot formation or charring at the ablation electrode of the RF catheter or air emboli were noted in any of the patients in either group.
Complications
No patients died in either of the 2 groups during the study period. No symptomatic neurological accidents, which were suggestive of a stroke, transient ischemic attack or systemic embolus, occurred in any of the patients in either of the 2 groups ( Table 2) . Among the patients who underwent MRI after the procedure, however, silent cerebral thromboembolic lesions were found in 1 of the 31 patients (3.2%) in group D and one of the 29 patients (3.4%) in group W, both of whom had no obvious neurological abnormalities.
In group D, no serious bleeding, including cardiac tamponade, occurred in any of the patients. In group W, however, cardiac tamponade occurred in 2 patients (2.0%; P=0.23), and they were successfully treated by percutaneous drainage without surgical intervention. The prevalence of minor bleeding associated with a groin hematoma was lower in group D than in group W (P=0.12). As a result, total bleeding complications occurred less frequently in group D (4.5%) than in group W (12.9%; P<0.05). Although all 5 patients who developed groin hematomas had no severe renal impairment, 3 (60%) of those patients also received drugs that might enhance the anticoagulant effect of dabigatran (amiodarone, n=1; verapamil, n=1) or a bleeding tendency (concomitant antiplatelet drug [aspirin], n=1; Table 3 ).
All patients were discharged with no clinical problems. No increase in pericardial effusions detected on transthoracic echocardiography and no other complications related to the procedure were observed in the outpatient clinic 2 weeks after the procedure and during a mean follow-up period of 7.1±2.8 months (range, 70-354 days).
Discussion
The present findings were as follows: (1) all patients who received dabigatran at a dose of 110 mg twice daily, could continue the dabigatran treatment through the study period except for the discontinuation on the day of the procedure; and (2) although the risk of thromboemboli was lower in the patients who received dabigatran than in those on warfarin, the use of dabigatran for periprocedural AF ablation did not cause any thromboembolic events, serious bleeding, or cardiac tamponade, and the prevalence of minor bleeding was comparable to that on warfarin.
Periprocedural Dabigatran in AF Ablation
The transseptal sheath placement and catheter manipulation within the LA, ablation evoking endothelial denudation and char formation, and atrial stunning for several weeks, or even months, result in a postprocedural increase in the risk of embolization around the time of RF catheter ablation for AF. 8 The thromboembolic risk can be minimized by adequate periprocedural anticoagulation, which could conversely increase the risk of bleeding complications. 8 Recent studies have shown that the continuation of therapeutic warfarin during the ablation procedure could reduce the risk of periprocedural strokes/ transient ischemic attacks without increasing the risk of hemorrhagic events. 4-9 In the present study, the prevalence of thromboembolic and bleeding complications in patients who continually received warfarin during the procedure were similar to that in previous studies, 4,6,7 indicating the efficacy and safety of continuing warfarin during the ablation procedure. The narrow therapeutic window, numerous drug and food interactions, and the need for frequent and inconvenient monitoring and adjustments of the dose, however, are troublesome and are disadvantages of warfarin use. 8,10, 13 Because it takes some time to reach a therapeutic range and determine the maintenance dose, the anticoagulant effect might be suboptimal for several days after the initiation of warfarin treatment.
Dabigatran is a direct thrombin inhibitor, and has a rapid onset of action (0.5-2 h) and few drug and food interactions. 21 Drug accumulation is dependent on the renal function and dabigatran dosing is based on the renal function. 22 The peak anticoagulant effect occurs within 2 h, which provides immediate anticoagulation without the concern for suboptimal and insufficient anticoagulation at the initiation of dabigatran use. Therefore, dabigatran seems to be easier to use and more suitable than warfarin as an anticoagulant to start around the ablation procedure. In 84 patients (76%) in group D, dabigatran was used for ≤15 days prior to the procedure in this study. Dabigatran may also have a greater possibility of reducing the period required for anticoagulation before AF ablation, as compared with warfarin.
The AF ablation periprocedural period requires anticoagulation simultaneously to avoid thromboembolic complications. 1-9 The RE-LY trial showed that 110 mg of dabigatran twice daily was associated with a lower rate of major hemorrhage, and 150 mg of dabigatran twice daily was associated with a similar rate of major hemorrhages compared with warfarin. 10 There is still limited information, especially on the optimal dose for Japanese patients, and there is no specific antidote to reverse the effects of dabigatran. Dabigatran is recommended to be discontinued at least 24 h before an invasive procedure. 22 Therefore, in the present study, we treated the patients with 110 mg dabigatran twice daily. Although the patients in group D received a lower dose, periprocedural dabigatran use prevented thromboembolic events around the ablation procedure as effectively as did dose-adjusted warfarin use. Furthermore, 110 mg dabigatran twice daily did not cause an increase in bleeding complications compared with warfarin use. And in group D, bleeding complications did not always occur in patients with high HAS-BLED score ( Table 3) . The elimination half-life ranges from 12 to 14 h when dabigatran is used for long-term therapy with a normal creatinine clearance. 23 Because dabigatran was discontinued on the morning of the procedure, there might have been a significant residual pharmacological effect during the ablation procedure in this study. The present results demonstrate the utility and safety of periprocedural dabigatran use, and the possibility that 110 mg twice daily might be appropriate in Japanese patients with a low risk of thromboembolism and no renal dysfunction.
Previous Studies
Recently, 2 studies on periprocedural dabigatran use have been reported. 24, 25 One reported that dabigatran was useful and safe, similar to the present results, even when it was started immediately after the AF ablation. 24 The other, however, showed that periprocedural dabigatran use significantly increased the risk of bleeding or thromboembolic complications compared with uninterrupted warfarin therapy. 25 In that study, all patients received the greater dose of 150 mg dabigatran twice daily, and a considerable number of patients had a high risk of thromboemboli (CHAD2 score ≥2), which might be related to the poor results. 10,11, 26 Further, in the present study, the body mass index in patients who received dabigatran was relatively small compared to that in the previous study. The difference in the patient background (ie, race, age, body frame, renal function etc), ablation procedure, or dose or period of dabigatran use may account for the differences in the results among the reported studies, including the present study.
Study Limitations
First, this study was a retrospective and non-blinded study with a small sample size. Second, the efficacy and safety of periprocedural dabigatran in patients with a high risk (high CHADS2 score) for a thromboembolism or renal dysfunction were not sufficiently evaluated. Third, all of the present patients were enrolled at a single, high-volume center with expertise in performing AF ablation and in maximizing the procedural safety, and the lack of complications may have been influenced by the operator experience and expertise. Therefore, multicenter studies with a larger number of patients, including patients with a high CHAD2 score and renal dysfunction, and longer followup period may be needed to confirm and enhance the present results.
Conclusions
Periprocedural dabigatran at a dose of 110 mg twice daily appears to be a safe strategy at least in Japanese patients undergoing AF ablation with a relatively low risk of thromboembolism and no severe renal dysfunction. It might also be able to be used as an alternative to continuous warfarin in the periprocedural AF ablation period in those kinds of AF patients.
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